Sandbox Reserved 1726

From Proteopedia

(Difference between revisions)

Revision as of 01:01, 31 March 2022

This Sandbox is Reserved from February 28 through September 1, 2022 for use in the course CH462 Biochemistry II taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1700 through Sandbox Reserved 1729.

To get started:

Click the edit this page tab at the top. Save the page after each step, then edit it again.
show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Anaplastic Lymphoma Kinase Extracellular Region

1 Background
2 Structure
3 Function
4 Disease and Medical Relevance
- 4.1 Cancer
- 4.2 Neuroblastoma

Background

Anaplastic Lymphoma Kinase (ALK) is a transmembrane receptor and a member of the family of Receptor Tyrosine Kinases (RTKs), a family of biomolecules that are primarily responsible for biosignaling pathways such as the insulin signaling pathway. It was discovered as a novel tyrosine phosphoprotein in 1994 in an analysis of Anaplastic Large-Cell Lymphoma, the protein's namesake. A full analysis and characterization of ALK was completed in 1997, properly identifying it as a RTK, and linking it closely to Leukocyte Tyrosine Kinase (LTK).

Structure

As previously mentioned, ALK is a close homolog of LTK, and together these two homologous proteins create a subgroup within the superfamily of insulin receptors (IR). ALK is composed of 1620 amino acids in total, with three primary domains. ALK is described as showing the "classic structural features of RTKs, with an extracellular ligand-binding domain, a transmembrane-spanning region, and an intracellular kinase domain." As displayed in Figure 1,

Figure 1. Overview of Anaplastic Lymphoma Kinase Structure

the intracellular tyrosine kinase domain ranges from residues 1116-1392, and features the C-terminal end. The transmembrane helical domain (TMH) bridges the gap between the intracellular and extracellular regions from residues 1039-1116. The final section of ALK is the extracellular region, which spans from residues 1025 to 1, and contains 8 domains. Of these 8 domains, two regions of the extracellular region can be found; one containing the ligand-binding site of the protein, and another lesser-known subregion. This lesser-known subregion contains 4 domains from residues 1-626; an N-terminal Region (NTR), two meprin–A-5 protein–receptor protein tyrosine phosphatase μ (MAM), and a low-density lipoprotein receptor class A (LDL) domain sandwiched between the two MAM domains. The presence of an LDL domain sandwiched by two MAM domains is a unique feature that ALK does not share with other RTKs. The purpose behind this unique difference is still unclear. The ligand-binding extracellular subregion is the most well-characterized of the two subregions, containing 4 distinct domains from residues 673-1025; a triple helix bundle (THB) domain, a glycine-rich domain (GlyR) that is also referred to as the poly-Glycine domain, a tumor necrosis factor-like (TNF-like), and an epidermal growth factor-like domain (EGF-like). All four domains of this subregion of the extracellular region contribute to ligand-binding.

Domains

Three Helix Bundle-like Domain

The mainly has a structural function overall as it interacts with the tumor necrosis factor-like domain upon ligand binding.

Poly-Glycine Domain

Figure 2. Rare Glycine helices on Anaplastic Lymphoma Kinase

Located between the three helix bundle-like domain and the tumor necrosis factor-like domain, the has an important structural role. The poly-Glycine domain also has a rare and unique structure of glycine helices with hexagonal hydrogen bonding shown in Figure 2. These glycine helices are unique to ALK's function among other tyrosine kinases, as these types of structures on the binding domain are not present.

The interacts with the three helix bundle-like domain to begin the conformational changes associated with ligand binding. The three helix bundle-like domain's α-helix interacts with the helix α-1' and β strand A-1'. This domain also assists in mediating ligand binding with the epidermal growth factor-like domain.

Epidermal Growth Factor-like Domain

The is very malleable and repositioning of this domain is essential for activation of the protein. This domain is able to undergo conformational changes with the ligand bound and when in contact with the tumor necrosis factor-like domain.

Binding Site

This site doesn't start out surrounding the ligand, instead the proximity of the ligand allows conformational changes across the protein. The ligands for ALK both have highly positively charged faces that interact with the TNF-like region^[1]. Salt bridges between the positively charged residues on the ligand and negatively charged residues on the receptor form are formed as the ligand approaches connecting the ligand with the receptor.

Ligands

The extracellular ligands of Anaplastic Lymphoma Kinase are ALKAL2 and ALKAL1.

ALKAL2

ALKAL2 (Anaplastic Lymphoma Kinase Ligand 2) is a ligand of ALK as well as LTK located in the extracellular region. The full-length ALKAL2 (dimeric) and ALKAL2-AD (monomeric) can both induce dimerization of ALK ^[2]. Structurally, ALKAL2 has a N-termical variable region and a conserved augmentor domain and tends to aggregate in the cell ^[2]. Overexpression of ALKAL2 has been linked to high-risk neuroblastoma in absence of an ALK mutation ^[3] and could potentially have therapeutic opportunities.

ALKAL1

ALKAL1 (Anaplastic Lymphoma Kinase Ligand 1) is a monomeric ligand of ALK, in addition to ALKAL2. Structurally, ALKAL1 and ALKAL2 contain an N-terminal variable region and a conversed C-terminal augmentor domain ^[2]. However, in ALKAL1, this N-terminal variable region is shorter, and shares no similar sequences to ALKAL2. Nevertheless, ALKAL1 shares a 91% sequence similarity with ALKAL2. Both ligands include a three helix bundle domain in their structures, with an extended positively charged surface which is used in ligand binding ^[2].

Dimerization of Anaplastic Lymphoma Kinase

After binding to one of its ligands, Anaplastic Lymphoma Kinase undergoes ^[4]. The dimerization causes trans-phosphorylation of specific tyrosine residues which in turn amplifies the signal. It has been presumed that the phosphorylation cascade activates ALK kinase activity ^[4].

Function

Anaplastic Lymphoma Kinase plays a role in cellular communication and in the normal development and function of the nervous system It is present largely in the developing nervous system of a fetus and newborn, and overtime the expression of ALK dwindles with age. In addition to being expressed heavily in the brain, ALK has been shown to be present in the small intestine, testis, prostate, and colon ^[5].

Disease and Medical Relevance

Cancer

In ALK fusion proteins, the ALK fusion partner may cause dimerization independent of ligand binding, causing oncogenic ALK activation ^[4]. The regulation of ALK dimerization by ALKAL points to clear ways to inhibit ALK activity and may offer new therapeutic strategies in multiple disease settings ^[1]. Studies have shown that approximately 70-80% of all patients who have Anaplastic Large Cell Lymphoma (ALCL) contain the genetic complex of the ALK gene and the nucleolar phosphoprotein B23, also called numatrin (NPM) gene translocation, creating the NPM-ALK complex. This chimeric protein is expressed from the NPM promoter, leading to the overexpression of the ALK catalytic domain. This overexpression of ALK is characteristic of most cancers that are linked to tyrosine kinases, as the overexpression of these proteins leads to uncontrollable growth ^[5].

Neuroblastoma

Mutations in Anaplastic Lymphoma Kinase have been shown to produce oncogenic activity and cause neuroblastoma.

References

↑ ^1.0 ^1.1 Li T, Stayrook SE, Tsutsui Y, Zhang J, Wang Y, Li H, Proffitt A, Krimmer SG, Ahmed M, Belliveau O, Walker IX, Mudumbi KC, Suzuki Y, Lax I, Alvarado D, Lemmon MA, Schlessinger J, Klein DE. Structural basis for ligand reception by anaplastic lymphoma kinase. Nature. 2021 Dec;600(7887):148-152. doi: 10.1038/s41586-021-04141-7. Epub 2021, Nov 24. PMID:34819665 doi:http://dx.doi.org/10.1038/s41586-021-04141-7
↑ ^2.0 ^2.1 ^2.2 ^2.3 Reshetnyak AV, Rossi P, Myasnikov AG, Sowaileh M, Mohanty J, Nourse A, Miller DJ, Lax I, Schlessinger J, Kalodimos CG. Mechanism for the activation of the anaplastic lymphoma kinase receptor. Nature. 2021 Dec;600(7887):153-157. doi: 10.1038/s41586-021-04140-8. Epub 2021, Nov 24. PMID:34819673 doi:http://dx.doi.org/10.1038/s41586-021-04140-8
↑ Borenas M, Umapathy G, Lai WY, Lind DE, Witek B, Guan J, Mendoza-Garcia P, Masudi T, Claeys A, Chuang TP, El Wakil A, Arefin B, Fransson S, Koster J, Johansson M, Gaarder J, Van den Eynden J, Hallberg B, Palmer RH. ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutation. EMBO J. 2021 Feb 1;40(3):e105784. doi: 10.15252/embj.2020105784. Epub 2021 Jan 7. PMID:33411331 doi:http://dx.doi.org/10.15252/embj.2020105784
↑ ^4.0 ^4.1 ^4.2 Huang H. Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces. Int J Mol Sci. 2018 Nov 2;19(11). pii: ijms19113448. doi: 10.3390/ijms19113448. PMID:30400214 doi:http://dx.doi.org/10.3390/ijms19113448
↑ ^5.0 ^5.1 Della Corte CM, Viscardi G, Di Liello R, Fasano M, Martinelli E, Troiani T, Ciardiello F, Morgillo F. Role and targeting of anaplastic lymphoma kinase in cancer. Mol Cancer. 2018 Feb 19;17(1):30. doi: 10.1186/s12943-018-0776-2. PMID:29455642 doi:http://dx.doi.org/10.1186/s12943-018-0776-2

Retrieved from "http://52.214.119.220/wiki/index.php/Sandbox_Reserved_1726"

@@ Line 10: / Line 10: @@
 The <scene name='90/904331/Thb_like_domain/1'>Three Helix Bundle-like Domain</scene> mainly has a structural function overall as it interacts with the tumor necrosis factor-like domain upon ligand binding.
 ==== Poly-Glycine Domain ====
-[[Image:Honeycomb.png|300 px|right|thumb|Figure 2. Rare Glycine helices on Anaplastic Lymphoma Kinase]]Located between the three helix bundle-like domain and the tumor necrosis factor-like domain, the <scene name='90/904331/Polyg_region1/1'>Poly-Glycine Region</scene> has an important structural role. The poly-Glycine domain also has a rare and unique structure with hexagonal hydrogen bonding shown in Figure 2.
+[[Image:Honeycomb.png|300 px|right|thumb|Figure 2. Rare Glycine helices on Anaplastic Lymphoma Kinase]]Located between the three helix bundle-like domain and the tumor necrosis factor-like domain, the <scene name='90/904331/Polyg_region1/1'>Poly-Glycine Region</scene> has an important structural role. The poly-Glycine domain also has a rare and unique structure of glycine helices with hexagonal hydrogen bonding shown in Figure 2. These glycine helices are unique to ALK's function among other tyrosine kinases, as these types of structures on the binding domain are not present.
-==== Tumor Necrosis Factor-like Domain ====
 The <scene name='90/904331/Tnf_like_domain/1'>Tumor Necrosis Factor-like Domain</scene> interacts with the three helix bundle-like domain to begin the conformational changes associated with ligand binding. The three helix bundle-like domain's α-helix interacts with the helix α-1' and β strand A-1'. This domain also assists in mediating ligand binding with the epidermal growth factor-like domain.
 ==== Epidermal Growth Factor-like Domain ====